D
ifferences in disease prevalence, clinical manifestations, and health outcomes exist between men and women. Sources for this variation range from biological differentiation at the cellular level to behavioral differences influenced by societal gender norms. Typically, biologically based differences between men and women are called "sex differences," whereas "gender differences" describe health differences related, at least in part, to societal constructs of gender (1) (2) (3) . For example, biological events unique to women, such as pregnancy and menopause, are probably associated with sex differences in occurrence of certain conditions or in response to some medical therapies (4 -8) . Gender differences probably exist in health-related perceptions and behaviors for women and men with medical conditions that are prevalent for both sexes (for example, heart disease and chronic pain) (9 -16) . Although sex and gender differences are theoretically distinct, they remain difficult to disentangle when differences between men and women in health outcomes and treatment effectiveness are being examined. For this reason, and for brevity, we hereafter refer to sex and gender differences collectively as "sex effects."
In the past 2 decades, recognition of the importance of sex effects for health outcomes and treatment heterogeneity has been growing. Beginning in 1993, the National Institutes of Health has issued policies requiring the inclusion of women and minorities in all clinical research and trial designs with valid analysis of sex effects or differences between racial and ethnic groups (17, 18) . Since then, the inclusion of women in clinical trials has increased (19, 20) , and sex effects have been identified for medications, such as nicotine replacement therapy, analgesics, and aspirin (13, 14, 21) . Recently, sex effects in adverse reactions led to sex-specific dosage recommendations for a widely used sedative (7) . Despite this progress, representation of women in clinical studies remains inadequate for many conditions (22) . Further, published clinical trials infrequently report sex effects or discuss the appropriateness of sex-specific analyses (19, 20, 23) . To advance the clinical evidence base and improve health outcomes for women, clinical research must include adequate numbers of women, appropriately conduct sexspecific analyses, and consistently report sex effects. Systematic reviews (SRs) are a key source of information for clinicians, researchers, and guideline panels. By synthesizing the overall body of evidence for key clinical and research questions, SRs could potentially make a unique contribution to the evaluation of sex effects. To our knowledge, however, the reporting of sex effects by SRs has not been previously examined.
Here, we use evidence mapping to systematically evaluate the reporting of sex effects by SRs examining a diverse set of interventions for chronic conditions common to women (that is, depression, diabetes, and chronic pain). Evidence mapping is an emerging approach that describes key characteristics of studies for a broad area of medicine (24 -26). Our evidence map
Data Sources and Searches
In collaboration with an expert reference librarian, we searched PubMed and Cochrane Database of Systematic Reviews to identify eligible SRs published after 1 October 2009 through 31 October 2014 for depression, 13 February 2015 for diabetes, and 27 February 2015 for chronic pain. Search strategies used Medical Subject Headings and free-text terms for the conditions of interest, eligible interventions, and SRs (Appendix Table 2 , available at www.annals.org). We restricted the search to the past 6 years because SRs are typically outdated within 5 years of publication (28), and our goal was to describe the current state of the clinical literature. In addition to electronic searching, we screened published reviews of reviews for eligible articles.
Study Selection and Quality Assessment
Eligible SRs evaluated interventions in several broad categories (that is, medications, behavioral interventions, supervised exercise, and quality improvement or organizational interventions). We also included condition-specific interventions, such as bariatric surgery for diabetes. Reviews that evaluated mixed conditions or multiple interventions must have reported results separately for at least 1 eligible condition or intervention. We included reviews of interventions in any setting, with any type of active or inactive comparator, and with any duration of follow-up. Detailed inclusion and exclusion criteria are provided in Appendix Table 3 (available at www.annals.org).
Two investigators screened citations for eligibility, and citations that were considered to be relevant by either person were retained for full-text review. Full-text articles were reviewed by 2 investigators, and disagreements were resolved through discussion or adjudicated by a third person.
Formal assessment of review quality was beyond the scope of this project. However, we noted whether reviews originated from organizations known for highquality reviews (that is, Cochrane Collaboration, Agency for Healthcare Research and Quality Evidencebased Practice Centers, and VHA ESP). For reviews reporting sex effects, we also assessed industry funding and whether statistical power was considered.
Data Abstraction
Data were abstracted by 1 investigator and reviewed by a second person. Disagreements were resolved by discussion or by a third reviewer. Abstracted data included the analysis method (that is, qualitative synthesis, meta-analysis, network meta-analysis, or individual-patient data [IPD] meta-analysis); clinical conditions; interventions; main outcomes; number and design of primary studies (for example, randomized, controlled trials [RCTs] or observational cohorts); proportion of women in the included primary studies; and if sex effects were part of the study aims, analysis plan, or results. For reviews reporting sex effects, we also recorded the number of primary studies used for sexspecific analyses, effect estimates, and the method used (for example, metaregression, subgroup analysis, or IPD meta-analysis).
All eligible reviews on depressive disorders and chronic pain conditions were fully abstracted. All diabetes reviews of nonpharmacologic interventions were also fully abstracted. For eligible diabetes medication reviews (n = 120), we applied an additional prioritization procedure before full abstraction. We prioritized reviews that examined multiple classes of medications or evaluated a single class of medications when 6 or fewer eligible reviews were identified. For SRs evaluating a single class (>6 eligible reviews were identified), we used additional prioritization criteria (for example, the most recent review published in a high-impact journal or work done by an organization known for highquality reviews). The remaining unselected but eligible reviews (n = 58) had a keyword text search for sex effects and were fully abstracted only when this search yielded positive results (n = 13). evaluate sex effects. Specifically, we examined quality improvement interventions and psychotherapy for depression; diet, physical activity, and culturally tailored psychoeducation for diabetes; behavioral interventions for chronic low back pain; and exercise interventions for chronic knee osteoarthritis. We chose these intervention-condition combinations because we either could not find any review reporting sex effects or located only reviews using suboptimal methods (that is, metaregression or qualitative synthesis).
For these interventions, we identified the largest recent eligible reviews and abstracted lists of primary RCTs as candidates for examination. We then determined which of the primary trials had randomly assigned at least 75 patients per treatment group and thus might be adequately powered to evaluate the interaction between sex and treatment effects (intervention × sex) (29) . We assessed whether sex effects were reported among the RCTs meeting this size requirement.
Role of the Funding Source
The VHA Quality Enhancement Research Initiative of the U.S. Department of Veterans Affairs funded this evidence map (VA-ESP Project 09-009; 2015) but had no involvement in data collection, analysis, interpretation of the results, or the decision to submit the manuscript for publication.
RESULTS

General Characteristics of the Evidence Base
We identified 313 eligible reviews for all conditions of interest, and we fully abstracted 268 of these ( Figure  1 ). For both diabetes and depression, the largest SRs focused on medications; reviews on chronic pain conditions were generally smaller, with the largest SRs addressing exercise (Appendix Figure, available at www .annals.org). We also found more eligible reviews for depression and diabetes than for chronic pain conditions ( Figure 1 ). Reviews on depression most frequently addressed psychotherapy (n = 44) and antidepressant medications (n = 24). Other interventions were evaluated by far fewer reviews (that is, combined psychotherapy and medications [n = 8], exercise [n = 7], Internet-delivered therapy [n = 4], quality improvement [n = 3], and guided self-help [n = 1]). Diabetes reviews most commonly evaluated medications (n = 120), and fewer examined exercise (n = 14); bariatric surgery (n = 12); or mixed behavioral (n = 6), dietary (n = 4), and quality improvement interventions (n = 3). Chronic pain reviews evaluated chronic low back pain (n = 26), knee osteoarthritis (n = 8), and fibromyalgia (n = 34). The most frequently evaluated interventions for chronic pain were exercise (n = 21), followed by systemic medications (n = 15), acupuncture and chiropractic manipulation (n = 12), topical medications or localized injections (n = 8), behavioral treatments (n = 8), combination interventions (n = 4), and quality improvement (n = 1).
Of 268 reviews that were fully abstracted, most were restricted to RCTs (73 for depression, 70 for diabetes, and 57 for chronic pain conditions) but only 14% (n = 37) originated from an organization known for high-quality reviews. Individual-patient data metaanalyses were also rare (n = 16 [6%]).
Sex Distribution of Included Primary Studies
Systematic reviews often did not report sex distribution of primary studies. For example, only 31% (n = 8) of reviews on chronic low back pain and 42% (n = 34) of diabetes reviews did so. However, most reviews on depression (n = 52 [60%]), knee osteoarthritis (n = 5 [63%]), and fibromyalgia (n = 23 [68%]) provided data on the proportion of female participants in primary studies. When reported, women constituted the majority of participants for depression interventions; however, few of the recent large reviews evaluating either psychotherapy or combined psychotherapy and medications reported sex distributions. Diabetes reviews reported that the number of female participants varied, with studies ranging from fewer than 30% to greater than 90%. Chronic pain reviews generally included primary studies with 50% or greater female participants; in particular, fibromyalgia studies had even greater female representation (median, 96%). * 114 of 159 eligible diabetes reviews were fully abstracted. The remaining 45 reviews received a keyword text search and were not further abstracted because of negative search results.
RESEARCH AND REPORTING METHODS Reporting of Sex Effects by Systematic Reviews on Interventions
Intervention Sex Effects
A small fraction of eligible SRs reported sex effects on intervention efficacy or the risk for adverse events. Sex effects were addressed by 16% (n = 14) of depression reviews (30 -43), whereas only 7% (n = 13) of diabetes reviews (44 -56) and 8% (n = 2) of chronic low back pain reviews (57, 58) did so. Detailed review characteristics and sex effects are provided in Appendix Table 4 (available at www.annals.org), and summary results are presented in the Table. We found no reviews reporting sex effects for knee osteoarthritis or fibromyalgia; examination of sex effects would be very difficult for fibromyalgia, given its much higher prevalence among women than men (3.4% vs. 0.5% for U.S. adults) (59).
Depression reviews reporting sex effects most frequently addressed antidepressant medications (n = 6) (30 -35); then psychotherapy (n = 5) (36 -40); and finally combined psychotherapy and medications (n = 1) (41), guided self-help (n = 1) (42), and collaborative care (n = 1) (43) (Figure 2 ). Diabetes reviews most often evaluated sex effects for medications (n = 10) (44 -53), and far fewer addressed bariatric surgery (n = 2) (54, 55) or diabetes self-management education (n = 1) (56) (Figure 2) . The 2 chronic low back pain reviews examined sex effects for medications (57) and pain rehabilitation programs (58).
Although most reviews used metaregression to evaluate sex effects, 9 used subgroup analysis or IPD meta-analysis (4 for depression [34, 35, 42 , 44] and 5 for diabetes [48, 50 -53]) ( Table 1) . Depression reviews used IPD meta-analyses to examine the efficacy of desvenlafaxine (34), duloxetine (35), and guided self-help (42) for reducing depressive symptoms; subgroup analysis was used in a review on collaborative care, also with the main outcome of reducing symptoms (43). Diabetes reviews used subgroup analyses to examine dipeptidyl peptidase-4 inhibitors as a class (50), linagliptin (52), vildagliptin (53), and pioglitazone (48); these reviews addressed various outcomes, including glyce- In addition, 2 diabetes reviews reported sex effects for bariatric surgery; 1 depression review examined sex effects for combined medications and psychotherapy; 1 depression review reported on guided self-help; and 2 reviews on chronic low back pain looked at sex effects for medications and pain rehabilitation programs, respectively. No reviews on knee osteoarthritis or fibromyalgia reported sex effects. SR = systematic review. mic control. One diabetes review applied both subgroup and IPD analyses to evaluate the efficacy of linagliptin for glycemic control (51). Both reviews reporting sex results for chronic low back pain used metaregression (57, 58) (Table) . Of note, most reviews examining sex effects did not discuss any consideration of statistical power required for detecting differences between men and women. In addition, all reviews using IPD meta-analysis had industry funding or conflicts of interest noted by the authors (34, 35, 42, 51) (Appendix Table 4 ).
We also examined the reporting of sex effects by depression and diabetes reviews per year and found no evidence of changing trends from 2010 to 2014 ( Figure 3) . The proportion of eligible depression reviews reporting sex effects was 11% to 26% (mean, 17%); the percentage of diabetes reviews presenting sex effects was 5% to 11% (mean, 8%). The 2 chronic low back pain reviews reporting sex effects were published in 2013 and 2014.
To evaluate whether trends have changed since 2014, we updated PubMed searches through 13 January 2016 and found an additional 91 eligible SRs (524 abstracts screened). Seven reviews (8%) reported sex effects (3 for depression [60 -62], 2 for diabetes [63, 64] , and 1 each for knee osteoarthritis [65] and fibromyalgia [66]), and 47 (52%) described the sex distribution of included primary studies. Two reviews used metaregression to evaluate sex effects (60, 62), 4 used subgroup or IPD techniques (61, 63-65), and 1 applied qualitative synthesis (66) (Appendix Table 5 , available at www.annals.org).
Primary RCTs: Evaluation of Sex Effects
To identify potential sex effects reported by primary RCTs, we examined trials included in the largest, most recent eligible SRs for selected interventions. For depression, we evaluated collaborative care (67) and psychotherapy (68). We found that all 21 RCTs on collaborative care had randomly assigned 75 or more participants per group, but only 2 RCTs evaluated subgroup effects by sex and found no effect on outcomes (69, 70). Only 11% of psychotherapy trials (n = 10 of 92) met the minimum sample size criterion, and 1 of these may have evaluated sex as a moderator (that is, "no demographic characteristic . . . moderated time to remission") (71).
For diabetes, we selected dietary (72), mixed behavioral (73), and culturally tailored psychoeducation (74) interventions. Six of 20 (30%) primary RCTs on dietary interventions (75-80) had a minimum of 75 participants per group; among these, 2 evaluated sex as a moderator and found no differential effects on glycemic control (76) or weight (78). Only 12% (n = 2 of 17) mixed behavioral RCTs (81, 82) met the sample size criterion, 1 of which reported a greater effect of physical activity on glycemic control in men than women (81). Of 33 psychoeducation RCTs, 11 met the sample size requirement (83-93) but only 1 of these evaluated sex effects and found no differences in glycemic control or diabetes knowledge (83).
We also examined exercise for knee osteoarthritis (94) and behavioral interventions for chronic low back pain (95). Seven of 30 (23%) back pain RCTs (96 -102) randomly assigned at least 75 participants per group, but none evaluated sex effects. Eight of 54 (15%) knee osteoarthritis RCTs (103-110) met the sample size requirement, 1 of which stated, "both sexes . . . showed similar improvement in self-reported disability, pain and 6-minute walk distance" (104).
DISCUSSION
To our knowledge, this is the first evaluation of the reporting of sex effects by SRs. Very few SRs reported sex effects, and they often failed to describe the proportion of women in primary studies. Of those reporting sex effects, most used metaregression instead of subgroup analysis or IPD meta-analysis. Metaregression is subject to ecological fallacy, potentially leading to incorrect inferences about relationships between outcomes and individual characteristics when actual associations being tested involve group characteristics; as such, metaregression is generally recommended only for study design characteristics (for example, primary vs. specialty care settings) (111, 112). In contrast, both subgroup and IPD meta-analyses are better suited to evaluate sex effects; in particular, IPD moderator analyses can directly assess whether sex interacts with intervention efficacy or the risk for adverse events (113).
To better understand the feasibility of conducting new SRs examining sex effects, we also evaluated a selection of primary RCTs for various interventions. Overall, we found that few RCTs had sufficient sample sizes to examine moderator effects. Of these, only 9 of 66 (14%) examined interactions between sex and the intervention group. The paucity of RCTs examining sex effects is disappointing but consistent with previous work evaluating published clinical trials (114, 115). Evaluation of sex effects by RCTs would be costly because of the larger sample sizes needed to examine moderator effects and additional resources needed to recruit an adequate number of women. Possible barriers to participation by women include fear and distrust of research, lack of transportation, and interference with work or family responsibilities (116). Meta-analyses would permit pooling of results from smaller trials, which would provide greater power to detect subgroup and moderator effects. However, metaregression, which is the technique most easily applied using published trial results, is not well-suited to examine sex effects. The IPD meta-analysis, which is the more robust approach for evaluating sex effects, could overcome small sample sizes or lower participation by women. However, obtaining patient-level data requires cooperation and sharing of data among investigators, capacity for data repositories, adequate protections for patient privacy (117), and greater statistical resources (113). Recent calls to require standardized sharing of IPD for published clinical trials (118), if heeded, could enable analyses capable of properly examining sex effects.
An intermediate step could be pooled subgroup analyses, using separate results for men and women reported by primary RCTs. These meta-analyses could employ published data and thus require fewer resources than IPD techniques. However, we identified few RCTs that reported such subgroup analyses, which may reflect concerns of the authors (and reviewers) about identifying spurious subgroup effects in underpowered studies (119, 120). Another explanation may be that subgroup analyses are being performed, but not reported, when no differences are found for men and women. Therefore, systematic and unbiased reporting of subgroup effects would be needed to support pooled analyses that accurately examined effects for women separately from men.
The following considerations may help prioritize interventions for the greater investment required for larger RCTs or IPD meta-analysis. Basic science, preclinical, or early-phase clinical studies suggest sex effects (for example, animal models and pharmacokinetics); observational studies or small RCTs indicate sex effects, but methodological limitations decrease confidence in their findings. Unique biological events (for example, menopause) or behavioral and sociocultural differences between women and men are particularly relevant for the disease process or treatment mechanism being considered.
For example, we can apply these considerations to the question of adverse effects for antidepressants. Antidepressants are used for a wide range of conditions, including depression and chronic pain. Pharmacokinetic evidence supports different antidepressant doses for men and women (121). Although data were limited and conflicting, our results also suggest that adverse effects may differ for men and women with some antidepressants. Because adverse effects are a major cause of poor adherence, a better understanding of sex effects for various antidepressants could help clinicians tailor treatment and improve outcomes.
Our study has several limitations. Evidence mapping gives a broad overview of the evidence base for important clinical and research questions and often includes multiple conditions or interventions. Because of this increased breadth of content, however, it does not permit formal evaluation of quality (for example, for risk of bias) for included studies. Our search was also limited to reviews published since 2009, so we may have missed older reviews, especially those that studied interventions with a smaller evidence base. Reviews finding no evidence of sex effects may simply have been underpowered. All IPD meta-analysis reviews were industry-funded and used conveniently available data sets instead of systematic searches to identify all eligible trials; they are at higher risk for bias.
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